Pureline Biolabs Ltd supplies research grade compounds strictly for laboratory and in vitro research purposes. By entering this site you confirm that:
Terms & Conditions · Privacy Policy
Pureline Biolabs Ltd · Company No. 17236739 · Registered in England & Wales · Not evaluated by the MHRA
A signaling peptide does not have one universal half-life. Its measured stability depends on sequence, exposed cleavage sites, terminal residues, conformation, biological matrix, renal clearance and the design of the experiment used to measure it.
Lyophilised peptide vials can differ in cake height, texture, colour and position even when their labelled peptide quantities are similar. This guide explains the formulation and freeze-drying variables behind those differences, what appearance can reveal, and what only laboratory analysis can establish.
Most UK peptide suppliers show a certificate. Far fewer show one that names them as the client and verifies on the testing lab’s own portal. Here is how to tell the difference in about a minute.
A 99% purity figure does not mean a 10mg vial contains 9.9mg of peptide. Here is what HPLC area-percent measures, what it leaves out, and why the difference matters when comparing suppliers.
“Lab tested”, “third-party verified”, “pharmaceutical grade”, “COA on request”. A plain-language guide to what each claim can legitimately mean, what it often means, and the one question that separates them.
What Research Use Only means for peptides in the UK, and what responsible research supply actually looks like.
How UK law treats peptides in 2026 — MHRA classification, what research use only actually means, advertising rules, chemical regulation and what a COA does and does not prove.
Peptide Guide · August 2026 Peptide Guides Types of Peptides Explained — A Classification Guide From dipeptides to polypeptides, the
Research Guide · August 2026 Research Guides How and Why to Reconstitute Peptides — Complete UK Guide Every lyophilised research
Regulatory Analysis · August 2026 Research Overviews The Transatlantic Split: Why the FDA and MHRA View Research Peptides Differently In
